Your browser is no longer supported. Please, upgrade your browser.
LH Laboratory Corporation of America Holdings monthly Stock Chart
Laboratory Corporation of America Holdings
IndexS&P 500 P/E22.86 EPS (ttm)8.60 Insider Own0.10% Shs Outstand97.40M Perf Week-1.29%
Market Cap18.76B Forward P/E10.32 EPS next Y19.04 Insider Trans-4.69% Shs Float96.84M Perf Month-4.86%
Income844.90M PEG1.84 EPS next Q6.97 Inst Own94.70% Short Float1.76% Perf Quarter12.74%
Sales12.44B P/S1.51 EPS this Y-7.70% Inst Trans1.25% Short Ratio2.38 Perf Half Y12.06%
Book/sh84.59 P/B2.32 EPS next Y-6.12% ROA4.70% Target Price245.27 Perf Year13.25%
Cash/sh6.99 P/C28.12 EPS next 5Y12.41% ROE11.20% 52W Range98.02 - 218.77 Perf YTD16.13%
Dividend- P/FCF12.34 EPS past 5Y7.10% ROI7.50% 52W High-10.20% Beta1.10
Dividend %- Quick Ratio1.20 Sales past 5Y14.00% Gross Margin31.10% 52W Low100.43% ATR6.29
Employees65000 Current Ratio1.40 Sales Q/Q33.00% Oper. Margin12.50% RSI (14)45.02 Volatility2.68% 3.13%
OptionableYes Debt/Eq0.71 EPS Q/Q219.40% Profit Margin6.80% Rel Volume0.72 Prev Close198.76
ShortableYes LT Debt/Eq0.67 EarningsOct 27 BMO Payout0.00% Avg Volume714.37K Price196.46
Recom1.80 SMA20-3.51% SMA50-0.11% SMA20011.68% Volume517,395 Change-1.16%
Jul-14-20Upgrade BofA Securities Neutral → Buy $194 → $220
Jul-13-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Resumed Deutsche Bank Buy $210
May-15-20Upgrade Mizuho Neutral → Buy $158 → $186
Apr-29-20Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-27-20Upgrade Wolfe Research Underperform → Peer Perform
Apr-27-20Upgrade Citigroup Neutral → Buy $204 → $214
Jan-08-20Initiated Wells Fargo Overweight $210
Jul-16-19Upgrade BofA/Merrill Underperform → Neutral
Jun-21-19Upgrade Deutsche Bank Hold → Buy $180 → $220
Apr-02-19Upgrade Jefferies Hold → Buy $154 → $190
Jan-17-19Initiated UBS Buy $169
Jan-03-19Downgrade BofA/Merrill Neutral → Underperform
Dec-03-18Downgrade Craig Hallum Buy → Hold
Oct-30-18Downgrade Argus Buy → Hold
Oct-25-18Downgrade Canaccord Genuity Buy → Hold $190 → $162
Oct-19-18Resumed BofA/Merrill Buy
Jun-07-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
May-01-18Upgrade Robert W. Baird Neutral → Outperform
Mar-23-18Initiated Argus Buy $202
Nov-25-20 09:04AM  
Nov-24-20 01:51PM  
Nov-20-20 08:55AM  
Nov-19-20 12:15PM  
Nov-18-20 12:45PM  
Nov-17-20 11:06AM  
Nov-16-20 11:40AM  
Nov-13-20 07:35AM  
Nov-12-20 09:26AM  
Nov-11-20 04:17PM  
Nov-10-20 09:16AM  
Nov-09-20 08:37AM  
Nov-05-20 09:56AM  
Nov-04-20 02:43PM  
Nov-03-20 12:27PM  
Nov-02-20 02:15PM  
Oct-30-20 12:57PM  
Oct-29-20 05:20PM  
Oct-28-20 10:58AM  
Oct-27-20 03:30PM  
Oct-26-20 09:30AM  
Oct-21-20 05:50PM  
Oct-20-20 12:31PM  
Oct-19-20 04:20PM  
Oct-17-20 01:08AM  
Oct-16-20 09:57AM  
Oct-13-20 12:10PM  
Oct-12-20 07:20AM  
Oct-09-20 05:50PM  
Oct-05-20 01:28PM  
Oct-03-20 10:48AM  
Oct-02-20 05:50PM  
Oct-01-20 10:59AM  
Sep-30-20 10:11AM  
Sep-29-20 06:58AM  
Sep-28-20 04:22PM  
Sep-24-20 09:20AM  
Sep-23-20 06:56AM  
Sep-21-20 05:50PM  
Sep-16-20 06:58AM  
Sep-14-20 05:50PM  
Sep-08-20 07:24AM  
Sep-03-20 05:50PM  
Sep-02-20 09:53AM  
Sep-01-20 04:23PM  
Aug-31-20 01:30PM  
Aug-28-20 05:50PM  
Aug-27-20 03:40PM  
Aug-26-20 02:59PM  
Aug-21-20 04:18PM  
Aug-20-20 08:02AM  
Aug-14-20 12:28PM  
Aug-11-20 07:00AM  
Aug-10-20 08:00AM  
Aug-06-20 12:55PM  
Aug-04-20 11:59AM  
Aug-03-20 11:05AM  
Jul-31-20 12:13PM  
Jul-30-20 03:43PM  
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular and infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other procedures. In addition, it provides a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, and QIAGEN N.V; and Ciox Health for the creation of COVID-19 patient data registry in the United States. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schroeder Mark SEVP, President-Diagnostics LabNov 06Sale214.59588126,1793,949Nov 10 10:48 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentNov 04Sale214.141,500321,2047,698Nov 06 09:06 AM
Williams R SandersDirectorJul 08Option Exercise98.491,300128,0376,395Jul 10 04:25 PM
Williams R SandersDirectorJul 08Sale173.121,300225,0565,095Jul 10 04:25 PM
van der Vaart Sandra DEVP, Chief Legal OfficerJul 02Sale170.0043573,9504,044Jul 07 09:38 AM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 24Sale160.33872139,8084,479Jun 26 10:06 AM
KING DAVID PDirectorMay 05Sale160.0031,2505,000,000312,554May 07 12:05 PM
Kirchgraber Paul RCEO, Covance Drug DevelopmentApr 03Option Exercise0.001,01008,459Apr 07 04:21 PM
Seltz Judith CEVP, CHROMar 10Buy168.5633055,625580May 04 10:18 AM
Seltz Judith CEVP, CHROFeb 28Buy174.9425043,735250May 04 10:18 AM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 21Sale189.6529756,326297Feb 25 12:59 PM
BELINGARD JEAN-LUCDirectorFeb 19Option Exercise77.193,100239,28941,161Feb 21 03:52 PM
BELINGARD JEAN-LUCDirectorFeb 19Sale189.7626,4795,024,75014,682Feb 21 03:52 PM
Williams R SandersDirectorFeb 13Sale188.491,227231,2775,095Feb 14 03:08 PM
van der Vaart Sandra DSVP, Global General CounselFeb 13Sale188.4920839,2062,736Feb 14 05:11 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 13Sale188.4918835,436486Feb 14 05:07 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 10Sale181.9910819,655300Feb 11 01:47 PM
van der Vaart Sandra DSVP, Global General CounselFeb 10Sale181.9913324,2052,529Feb 11 01:45 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.